GenSci Expects Topical Molgramostim Gel Approval in 2007

GeneScience Pharmaceuticals Co., Ltd. (GenSci) announced today
that the company's new drug, Genfulin(TM), a topical gel indicated for
the treatment of wound healing, is expected to get approval by China's
SFDA in early 2007.

The active ingredient in Genfulin(TM) is molgramostim (human
granulocyte-macrophage colony stimulating factor, hGM-CSF (rDNA
origin). GenSci has been the top biopharmaceutical manufacturer for
Jintropin(TM) somatropin (human growth hormone, hGH), Scimax(TM)
filgrastim (human granulocyte colony stimulating factor, G-CSF) and
molgramostim in China.

"With the unique innovative formulation, Genfulin(TM) marks the
major step in GenSci's transition to manufacturing biological
supergenerics," according to Dr. Lei Jin, CEO of GenSci.

Based on the current indications of molgramostim, Genfulin(TM) gel
was designed for new indications in wound healing with its novel and
unique formulation. Most importantly, clinical trials of Genfulin(TM)
have confirmed its efficacy in actively accelerating wound healing,
increasing wound tearing-resistance, and reducing, even avoiding, scar
proliferation in burn patients. Similar effects have also been
observed in chronic ulcer patients, including those with diabetic foot
ulcer. Overall, Genfulin(TM) gel has been shown to improve the quality
of wound healing significantly with a good safety profile, according
to results obtained from clinical trials.

Genfulin(TM) gel is applied to wound areas directly in patients
with burn, scald or ulcer to speed up the healing. GenSci holds a
patent for Genfulin(TM), which was developed with GenSci's proprietary
technology platform by scientists at GenSci.

Genfulin, Jintropin, Scimax are trademarks of GenSci.

About GenSci

GenSci (www.gensci-china.com) is the leading Chinese
biopharmaceutical company that develops, manufactures and markets
biological therapeutics focused on endocrinology and related areas,
aiming at providing affordable and innovative biopharmaceutical
products to patients. The company is privately-held and headquartered
in Changchun, China. Products include: Jintropinsomatropin (rhGH for
injection), Jintropin AQ somatropin liquid pen, Scimax filgrastim
(rhG-CSF injection), Granmac molgramostim (rhGM-CSF for injection),
Jintrotide (octreotide acetate for injection) and Jintrirelin
(triptorelin acetate injection). For more information, visit
www.gensci-china.com.